🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06950164
Active, not recruiting Observational

Dynamic Changes of Ductus Arteriosus in < 31 Weeks Preterm Infants: an Observational Study

NCT06950164 · tracked via the Priya Life Science China tracker
Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase
Observational
Started
2025-04-01
Last updated
2025-04-30

Condition(s) studied

PretermDuctus Arteriosus

Investigational drug(s) / intervention(s)

observation groupcontrol group

observation group: in the group, no intervention was given, and the preterm infants were diagnosed with respiratory distress syndrome(RDS)

control group: in the group, no intervention was given, but the preterm infants were diagnosed without respiratory distress syndrome(RDS)

Study summary

The ductus arteriosus quickly closes itself. is an important channel connecting the maternal fetal circulation before birth. After birth, this ductus arteriosus generally no longer has a physical function, so ductus arteriosus quickly closes itself. The persistent presence of ductus arteriosus leads to significant pressure changes in the systemic and pulmonary circulation, which have adverse effects on extremely/very premature infants. Therefore, persistent patent ductus arteriosus (PDA) is a systemic disease.

Eligibility

Sex
ALL
Min age
1 Minute
Max age
1 Hour
Healthy volunteers
No
Inclusion Criteria: * less than 32 weeks' gestational age * admission with 1 hours after birth Exclusion Criteria: * congenital abnormalities * parents' refusal

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Women and Children's hospital of Chonqing Medical University Chongqing Chongqing Municipality

More Daping Hospital and the Research Institute of Surgery of the Third Military Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06950164 on ClinicalTrials.gov ↗ ← All trials in China